Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

Early intervention is crucial, as childhood obesity can lead to long-term health issues such as diabetes and heart disease. PAY ATTENTION: Briefly News is now on YouTube! Check out our interviews on ...